Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma

BBA Clinical

Volumn 6, Issue , 2016, Pages 138-142

  Karabulut, Senem ^a   Afsar, Cigdem Usul ^b   Karabulut, Mehmet ^c   Alis, Halil ^c   Bozkurt, Mehmet Abdussamet ^c   Aydogan, Fatma ^a   Serilmez, Murat ^a   Tas, Faruk ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Istanbul Education and Research Hospital ^*  (Turkey)

^c BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Diagnostic; Omentin; Pancreatic adenocancer; Serum

Indexed keywords

ADIPOCYTOKINE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HEMOGLOBIN; LACTATE DEHYDROGENASE; OMENTIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LEUKOCYTE COUNT; LIVER METASTASIS; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT RESPONSE;

EID: 84992401657     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2016.10.002     Document Type: Article

References (19)

1. [1] Jemal, A., Bray, F., Center, M.M., et al. Global cancer statistics. CA Cancer J. Clin. 61:2 (2011), 69–90.
2. [2] O'Rorke, M.A., Cantwell, M.M., Cardwell, C.R., et al. Can physical activity modulate pancreatic cancer risk? A systematic review and meta-analysis. Int. J. Cancer, 126, 2010, 2957.
3. [3] Arslan, A.A., Helzlsouer, K.J., Kooperberg, C., et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch. Intern. Med., 170, 2010, 791.
4. [4] Aune, D., Greenwood, D.C., Chan, D.S., et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann. Oncol., 23, 2012, 843.
5. [5] De Pergola, G., Silvestris, F., Obesity as a major risk factor for cancer. J. Obes., 2013, 2013, 291546.
6. [6] Booth, A., Magnuson, A., Fouts, J., Foster, M., Adipose tissue, obesity and adipokines: role in cancer promotion. Horm. Mol. Biol. Clin. Invest. 21:1 (2015), 57–74.
7. [7] Park, J., Scherer, P.E., Adipocyte-derived endotrophin promotes malignant tumor progression. J. Clin. Investig. 122:11 (2012), 4243–4256, 10.1172/jci63930.
8. [8] Yang, R.Z., Lee, M.J., Hu, H., Pray, J., Wu, H.B., Hansen, B.C., Shuldiner, A.R., Fried, S.K., McLenithan, J.C., Gong, D.W., Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 290 (2006), 1253–1261.
9. [9] Ohashi, K., Shibata, R., Murohara, T., Ouchi, N., Role of antiinflammatory adipokines in obesity-related diseases. Trends Endocrinol. Metab. 25 (2014), 348–355.
10. [10] Zhang, Y.Y., Zhou, L.M., Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. Eur. J. Pharmacol. 698 (2013), 137–144.
11. [11] Fazeli, M.S., Dashti, H., Akbarzadeh, S., Assadi, M., Aminian, A., Keramati, M.R., et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine 62:1 (2013), 81–85.
12. [12] Uyeturk, U., Sarıcı, H., Kın Tekce, B., Eroglu, M., Kemahlı, E., Uyeturk, U., et al. Serum omentin level in patients with prostate cancer. Med. Oncol., 31(4), 2014, 923.
13. [13] Uyeturk, U., Alcelik, A., Aktas, G., Tekce, B.K., Post-treatment plasma omentin levels in patients with stage III colon carcinoma. J. BUON 19:3 (2014), 681–685.
14. [14] Shen, X.D., Zhang, L., Che, H., Zhang, Y.Y., Yang, C., Zhou, J., et al. Circulating levels of adipocytokine omentin-1 in patients with renal cell cancer. Cytokine 77 (2016), 50–55.
15. [15] Sit, M., Aktas, G., Yilmaz, E.E., Alcelik, A., Terzi, E.H., Tosun, M., Effects of the inflammatory response on serum omentin levels in early acute and chronic pancreatitis. Clin. Ter. 165:2 (2014), e148–e152.
16. [16] Aleksandrova, K., di Giuseppe, R., Isermann, B., Biemann, R., Schulze, M., Wittenbecher, C., et al. Circulating omentin as a novel biomarker for colorectal cancer risk: data from the EPIC-Potsdam cohort study. Cancer Res. 76:13 (2016), 3862–3871.
17. [17] Wali, A., Siddiq, F., Kanakapalli, D., Liu, Z., Lonardo, F., Rishi, A.K., et al. Intelectin overexpression causes chromosomal aberrations in immortalized human mesothelial cells. Proc Am. Assoc. Cancer Res., 47, 2006, 2544.
18. [18] Tan, B.K., Adya, R., Farhatullah, S., Chen, J., Lehnert, H., Randeva, H.S., Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 59 (2010), 3023–3031.
19. [19] Wu, S.S., Liang, Q.H., Liu, Y., Cui, R.R., Yuan, L.Q., Liao, E.Y., Omentin-1 stimulates human osteoblast proliferation through PI3K/Akt signal pathway. Int. J. Endocrinol., 2013, 2013, 368970.